JPH01275511A - External drug for skin - Google Patents
External drug for skinInfo
- Publication number
- JPH01275511A JPH01275511A JP10348188A JP10348188A JPH01275511A JP H01275511 A JPH01275511 A JP H01275511A JP 10348188 A JP10348188 A JP 10348188A JP 10348188 A JP10348188 A JP 10348188A JP H01275511 A JPH01275511 A JP H01275511A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- acid
- uric acid
- betaines
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title abstract description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940116269 uric acid Drugs 0.000 claims abstract description 20
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims description 24
- 230000000694 effects Effects 0.000 abstract description 28
- -1 uric acid glycoside Chemical class 0.000 abstract description 19
- 230000007306 turnover Effects 0.000 abstract description 14
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract description 12
- 229960003237 betaine Drugs 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 6
- 230000001815 facial effect Effects 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 5
- MFGPUMDDJCTHOI-BKKZJBRMSA-N 3-[(3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,9-dihydropurine-2,6,8-trione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)OC1N1C(=O)NC(=O)C2=C1NC(=O)N2 MFGPUMDDJCTHOI-BKKZJBRMSA-N 0.000 abstract description 4
- ICPDLDAJUABCSP-UHFFFAOYSA-N 3-dodecyl-7,9-dihydropurine-2,6,8-trione Chemical compound O=C1NC(=O)N(CCCCCCCCCCCC)C2=C1NC(=O)N2 ICPDLDAJUABCSP-UHFFFAOYSA-N 0.000 abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 3
- 239000004472 Lysine Substances 0.000 abstract description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 3
- 229930182470 glycoside Natural products 0.000 abstract description 3
- 229910052708 sodium Inorganic materials 0.000 abstract description 3
- 239000011734 sodium Substances 0.000 abstract description 3
- ODCYDGXXCHTFIR-UHFFFAOYSA-N 3-Methyluric acid Chemical compound O=C1NC(=O)N(C)C2=C1NC(=O)N2 ODCYDGXXCHTFIR-UHFFFAOYSA-N 0.000 abstract description 2
- IYQSDWNYZAHFOV-UHFFFAOYSA-N Homalin Natural products CN1CCCN2CCCCN(CCCN(C)C(Cc3ccccc3)C2=O)C(=O)C1Cc4ccccc4 IYQSDWNYZAHFOV-UHFFFAOYSA-N 0.000 abstract description 2
- 150000007968 uric acids Chemical class 0.000 abstract 3
- 206010040849 Skin fissures Diseases 0.000 abstract 2
- 238000013329 compounding Methods 0.000 abstract 2
- FCZAGKZBWFLIJT-UHFFFAOYSA-N 9-butyl-3,7-dihydropurine-2,6,8-trione Chemical compound N1C(=O)NC(=O)C2=C1N(CCCC)C(=O)N2 FCZAGKZBWFLIJT-UHFFFAOYSA-N 0.000 abstract 1
- LNCIXDIFZNXBDP-NSOVKSMOSA-N Homaline Chemical compound C1([C@H]2N(C)CCCN(C(C2)=O)CCCCN2CCCN([C@@H](CC2=O)C=2C=CC=CC=2)C)=CC=CC=C1 LNCIXDIFZNXBDP-NSOVKSMOSA-N 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 71
- 239000006071 cream Substances 0.000 description 27
- 239000000203 mixture Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 206010013786 Dry skin Diseases 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 125000004494 ethyl ester group Chemical group 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003205 fragrance Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000049 pigment Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007102 metabolic function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000036548 skin texture Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- CJKONRHMUGBAQI-YFKPBYRVSA-N (2s)-2-(trimethylazaniumyl)propanoate Chemical compound [O-]C(=O)[C@H](C)[N+](C)(C)C CJKONRHMUGBAQI-YFKPBYRVSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JUVFIIFIGXEMPN-UHFFFAOYSA-N 1-butyl-7,9-dihydro-3H-purine-2,6,8-trione Chemical compound OC1=NC=2NC(N(C(C=2N1)=O)CCCC)=O JUVFIIFIGXEMPN-UHFFFAOYSA-N 0.000 description 1
- PYKDRCOQHVRXTE-UHFFFAOYSA-N 1-ethyl-7,9-dihydro-3h-purine-2,6,8-trione Chemical compound O=C1N(CC)C(=O)NC2=C1NC(=O)N2 PYKDRCOQHVRXTE-UHFFFAOYSA-N 0.000 description 1
- QFDRTQONISXGJA-UHFFFAOYSA-N 1-methyluric acid Chemical compound O=C1N(C)C(=O)NC2=C1NC(=O)N2 QFDRTQONISXGJA-UHFFFAOYSA-N 0.000 description 1
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 description 1
- WVLFZLFLLJQWOR-UHFFFAOYSA-N 7,9-dihydro-3h-purine-2,6,8-trione;potassium Chemical compound [K].N1C(=O)NC(=O)C2=C1NC(=O)N2 WVLFZLFLLJQWOR-UHFFFAOYSA-N 0.000 description 1
- ILZWHRVULMLRLY-UHFFFAOYSA-N 7-butyl-3,9-dihydropurine-2,6,8-trione Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2CCCC ILZWHRVULMLRLY-UHFFFAOYSA-N 0.000 description 1
- QONZYGZXCZVJSJ-UHFFFAOYSA-N 9-dodecyl-3,7-dihydropurine-2,6,8-trione Chemical compound N1C(=O)NC(=O)C2=C1N(CCCCCCCCCCCC)C(=O)N2 QONZYGZXCZVJSJ-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- XTFQIRIHLGODFV-NSHDSACASA-N L-phenylalanine betaine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CC=CC=C1 XTFQIRIHLGODFV-NSHDSACASA-N 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 244000280244 Luffa acutangula Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000277269 Oncorhynchus masou Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- FOFYPMPFTYORPL-UHFFFAOYSA-N azanium;2,8-dioxo-7,9-dihydro-3h-purin-6-olate Chemical compound N.N1C(=O)NC(=O)C2=C1NC(=O)N2 FOFYPMPFTYORPL-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野コ
本発明は皮膚外用剤、特に肌あれの予防及び改善に用い
られる皮膚外用剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a skin preparation for external use, and particularly to a skin preparation for use in preventing and improving rough skin.
[従来の技術]
一般に皮膚外用剤には、化粧品、医薬品、医薬部外品な
どがあり、特に肌あれの防止及び改善を目的とした皮膚
外用剤については、従来より天然物から抽出した原料を
はじめとし、種々の原材料を配合して使用されている。[Prior Art] In general, external skin preparations include cosmetics, pharmaceuticals, quasi-drugs, etc. In particular, external skin preparations aimed at preventing and improving rough skin have conventionally been made using raw materials extracted from natural products. It is used in combination with various raw materials.
すなわち、たとえば、ヘチマエキスやプラセンターエキ
スなどの抽出エキス、マルメロ等の天然高分子、コラー
ゲン等の蛋白質、キチン等の多糖類、アルギニン等の単
体のアミノ酸、ビタミンE等の皮膚賦活剤あるいはグリ
セリン等の保湿剤などが肌あれの防止及び改善を目的と
して盛んに皮膚外用剤に用いられ、今日に至っている。That is, for example, extracted extracts such as loofah extract and placenta extract, natural polymers such as quince, proteins such as collagen, polysaccharides such as chitin, single amino acids such as arginine, skin activators such as vitamin E, or glycerin, etc. Moisturizers and the like are actively used in external skin preparations for the purpose of preventing and improving rough skin, and have continued to this day.
[発明が解決しようとする課題]
藍敦技術例皿■盃
しかしながら、これら従来の肌あれの防止及び改善に用
いられてきた物質は、顔面皮膚の皮脂量や水分が少ない
ことに起因する肌あれの防止及び改善を対象にして使用
されており、最近の論文(Development o
f a 5cientific Method for
C1assification of Facial
5kin Types、 Hiroko Kumag
ai et al : VIIICongreso
International de 1a 1. F、
S、 C,C,vol、1〜19.1984)で明ら
かになっている別種の肌あれ、つまり皮脂量が多く皮丘
皮溝が不鮮明で落屑が見られるようなタイプの肌あれの
防止及び改善にはまったく効果は認められず、したがっ
て広範囲のタイプの皮膚の正常化に対して、充分な効果
を期待することは出来ないという問題点を有していた。[Problem to be solved by the invention] Ai Atsushi Technique Example Dish Cup However, these conventional substances that have been used to prevent and improve skin roughness are not suitable for skin roughness caused by a low amount of sebum and moisture in the facial skin. It has been used for the prevention and improvement of
f a 5 scientific method for
C1assification of Facial
5kin Types, Hiroko Kumag
ai et al: VIIICongreso
International de 1a 1. F,
S, C, C, vol. 1-19. 1984), the prevention of another type of skin roughness, that is, the type of skin roughness with a large amount of sebum, indistinct skin mounds and skin folds, and exfoliation. There was a problem in that no improvement effect was observed at all, and therefore a sufficient effect could not be expected for the normalization of a wide range of skin types.
元肌q且首
本発明は前記従来技術の問題点に鑑がみなされたもので
あり、その目的はあらゆる肌あれの防止及び改善効果に
優れ、更に安全性、安定性の面からも優れた皮膚外用剤
を提供することにある。The present invention has been made in consideration of the problems of the prior art described above, and its purpose is to provide an excellent prevention and improvement effect on all kinds of skin roughness, as well as excellent safety and stability. The purpose of the present invention is to provide external preparations for the skin.
前記目的を達成するために、本発明者らはあらゆる種類
の肌あれの防止及び改善に対して効果を有し、更に安全
性、安定性の面からも満足できる物質を得るべく鋭意研
究を重ねた結果、尿酸及びその誘導体、あるいはベタイ
ン類及びそれらの塩からなる群から選ばれた一種または
二種以上の化合物を配合して得られる皮膚外用剤が、あ
らゆる種類の肌あれの防止及び改善に対して極めて有用
であることを見出し、本発明を完成するに至った。In order to achieve the above object, the present inventors have conducted extensive research in order to obtain a substance that is effective in preventing and improving all types of skin roughness and is also satisfactory in terms of safety and stability. As a result, external skin preparations obtained by blending one or more compounds selected from the group consisting of uric acid and its derivatives, or betaines and their salts have been shown to be effective in preventing and improving all types of skin roughness. The present inventors have discovered that the present invention is extremely useful for patients with disabilities, and have completed the present invention.
[課題を解決するための手段]
すなわち、請求項1記載の発明は、尿酸及びその誘導体
からなる群より選ばれた一種または二種以上の化合物を
含むことを特徴とする皮膚外用剤である。[Means for Solving the Problems] That is, the invention according to claim 1 is an external skin preparation characterized by containing one or more compounds selected from the group consisting of uric acid and its derivatives.
また、請求項2記載の発明は、ベタイン類及びそれらの
塩からなる群より選ばれた一種または二種以上の化合物
を含むことを特徴とする皮膚外用剤である。Moreover, the invention according to claim 2 is an external skin preparation characterized by containing one or more compounds selected from the group consisting of betaines and their salts.
そして、本発明者らは、尿酸及びその誘導体、あるいは
ベタイン類及びそれらの塩を配合すると単に肌あれの防
止及び改善のみならず、角質層のターンオーバー速度を
速くすることも認め、本発明を発展させている。The present inventors also recognized that blending uric acid and its derivatives, or betaines and their salts not only prevents and improves rough skin, but also accelerates the turnover rate of the stratum corneum, and has developed the present invention. It is being developed.
すなわち、老化皮膚においては細胞代謝の低下により角
質層のターンオーバー速度が遅くなることが観察されて
おり、このことから、刺激をともなわずにターンオーバ
ー速度を速くする物質は細胞代謝機能を再生し、ひいて
は老化皮膚を若返らせることができると考えられている
ので、本発明の皮膚外用剤は老化防止としても有用であ
ることが示唆された。In other words, it has been observed that in aging skin, the turnover rate of the stratum corneum slows down due to a decline in cell metabolism, and from this fact, substances that increase the turnover rate without stimulation may regenerate cell metabolic function. It is believed that the skin external preparation of the present invention is also useful for preventing aging, as it is believed that it can rejuvenate aging skin.
以下、本発明の構成について詳述する。Hereinafter, the configuration of the present invention will be explained in detail.
びその を む
本発明に用いられる尿酸及びその誘導体としては、尿酸
、尿酸ナトリウム、尿酸カリウム、尿酸アンモニウム等
の尿酸またはその塩、3−N−メチル尿酸、3−N−ラ
ウリル尿酸、7−N−ブチル尿酸、1−N−エチル尿酸
、9−N−ラウリル尿酸、3.7−N−ジメチル尿酸な
どの尿酸N−アルキル変性物、3−N−リボシル尿酸、
9−N−グリコジル尿酸などの尿酸配糖体などが挙げら
れる。Examples of uric acid and its derivatives used in the present invention include uric acid, uric acid or its salts such as sodium urate, potassium urate, ammonium urate, 3-N-methyluric acid, 3-N-lauryluric acid, 7-N- N-alkyl uric acid modified products such as butyluric acid, 1-N-ethyluric acid, 9-N-lauryluric acid, 3.7-N-dimethyluric acid, 3-N-ribosyluric acid,
Examples include uric acid glycosides such as 9-N-glycodyluric acid.
これらの尿酸及びその塩や尿酸配糖体は血清中にも見出
されており、哺乳類の平均生存年齢と血清中尿酸濃度と
の関連や、癌の発生率と血清尿酸値との関連より最近注
目されている物質であるが、外用としての適用例は現在
のところ見当らない。These uric acid, its salts, and uric acid glycosides are also found in serum, and recently the relationship between the average survival age of mammals and serum uric acid concentration, and the relationship between cancer incidence and serum uric acid level have been studied. Although this substance is attracting attention, there are currently no examples of its application for external use.
かかる尿酸及びその誘導体の皮膚外用剤への配合量は外
用剤全量に対してとくに限定されないが、通常配合量は
、0.001〜0.5重量%である。The amount of uric acid and its derivatives incorporated into the skin external preparation is not particularly limited, but the amount is usually 0.001 to 0.5% by weight based on the total amount of the external preparation.
0.001重量%未満では肌あれの防止及び改善効果な
らびに皮膚角質層のターンオーバー速度を速くする効果
が乏しくなる傾向があり、逆に0゜5重量%をこえて配
合しても効果の大きな増加は望めない。If it is less than 0.001% by weight, the effect of preventing and improving skin roughness and increasing the turnover rate of the skin's stratum corneum tends to be poor; There is no hope for an increase.
ベタイン およびそれらの塩を む皮 用作本発明に
用いられるベタイン類としては、リジンベタイン、オル
ニチンベタイン、ホマリン、トリゴネリン、アラニンベ
タイン、タウロベタイン、カルニチン、スタキドリン、
グルタミン酸ベタイン、フェニルアラニンベタイン、γ
−ブチロベタイン、ベタインなどが挙げられる。The betaines used in the present invention include lysine betaine, ornithine betaine, homarin, trigonelline, alanine betaine, taurobetaine, carnitine, stachydrine,
Glutamate betaine, phenylalanine betaine, γ
-Butyrobetaine, betaine and the like.
これらのベタイン類またはその塩は海藻中や魚類、甲殻
類に見出されているが、その生理学上の存在意義は必す
しも明らかになっておらず、外用剤としての適用例は現
在のところ見当らない。These betaines or their salts are found in seaweed, fish, and crustaceans, but their physiological significance is not necessarily clear, and there are currently no examples of their use as external preparations. I can't find it.
かかるベタイン類およびそれらの塩の皮FM外用剤への
配合量は外用剤全量に対してとくに限定されないが、通
常配合量は、0.001〜5重量%程壁量ある。The amount of such betaines and their salts added to the skin FM external preparation is not particularly limited to the total amount of the external preparation, but the amount usually is about 0.001 to 5% by weight.
0.001重量%未満では肌あれの防止及び改善効果な
らびに皮膚角質層のターンオーバー速度を速くする効果
が乏しくなる傾向があり、逆に5重量%をこえて配合し
ても効果の大きな増加は望めない。If it is less than 0.001% by weight, the effect of preventing and improving skin roughness and increasing the turnover rate of the skin's stratum corneum tends to be poor.On the other hand, if it is added more than 5% by weight, the effect will not increase significantly. I can't hope.
本発明の尿酸及びその誘導体、あるいはベタイン類およ
びそれらの塩は水に易溶で、油脂や有機性溶媒には不溶
または溶けにくい物質であるが、懸濁状態でも皮膚外用
剤への配合は可能であり効果に対して何の影響も与えな
い。The uric acid and its derivatives, or betaines and their salts of the present invention are easily soluble in water and insoluble or poorly soluble in oils and fats and organic solvents, but they can be incorporated into external skin preparations even in a suspended state. and has no effect on the effect.
本発明の皮膚外用剤は、皮膚化粧料として用いることが
好適であり、一般の皮膚化粧料に配合される通常の成分
、たとえば油分、水、界面活性剤、保湿剤、低級アルコ
ール、増粘剤、キレート剤、色素、防腐剤、香料などを
必要に応じて適宜配合することができる。The external skin preparation of the present invention is suitable for use as a skin cosmetic, and contains common ingredients that are included in general skin cosmetics, such as oil, water, surfactants, humectants, lower alcohols, and thickeners. , a chelating agent, a pigment, a preservative, a fragrance, etc. can be added as appropriate.
なお、本発明にかかる皮膚外用剤は、皮膚に使用するも
のを広く指し、例えば、化粧水、乳液、クリーム、パッ
クなどのフエーシャル化粧料やファンデーション等の皮
膚化粧料に代表される。The external skin preparation according to the present invention broadly refers to those used on the skin, and is typified by facial cosmetics such as lotions, milky lotions, creams, and packs, and skin cosmetics such as foundations.
また、尿酸及びその誘導体、ベタイン類及びそれらの塩
を併せ配合することも可能である。It is also possible to combine uric acid and its derivatives, betaines and their salts.
[実施例] 次に実施例により本発明を更に詳細に説明する。[Example] Next, the present invention will be explained in more detail with reference to Examples.
なお、本発明はこれによって限定されるものではない。Note that the present invention is not limited to this.
また、配合量は重量%で示している。Moreover, the blending amount is shown in weight%.
およびその−の【
まず、尿酸およびその誘導体を用いた本発明にかかる皮
膚外用剤の比較試験を行なった。and its - [ First, a comparative test was conducted on the skin external preparation according to the present invention using uric acid and its derivatives.
比較試験に供したクリームの組成を第1表に示す。Table 1 shows the composition of the cream used in the comparative test.
丈H排h」覇34
第1表
なお、まず第1表に記載されているB相を加熱し、70
℃に保った。これにA相を加え予備乳化後ホモミキサー
で均一に乳化し、次いで徐冷してクリーム(実施例1〜
4.比較例)を調製した。Table 1 First, phase B listed in Table 1 was heated to 70
It was kept at ℃. Phase A was added to this, and after preliminary emulsification, it was uniformly emulsified with a homomixer, and then slowly cooled to create a cream (Examples 1 to 3).
4. Comparative Example) was prepared.
第1表の各クリームをパネル(22才〜32才の女性)
5名の顔の右半分に一日2回、連続2力月間塗布した。Panels with each cream in Table 1 (women between 22 and 32 years old)
It was applied to the right half of five people's faces twice a day for two consecutive months.
試験終了後に顔の左右両方の塗布部の肌を皮膚インピー
ダンスとレプリカ法により測定し、皮膚のしっとり感と
皮膚のきめこまやかさを観察した。After the test was completed, the skin at the applied areas on both the left and right sides of the face was measured using the skin impedance and replica method, and the moist feeling and fineness of the skin were observed.
皮膚インピーダンスは、増圧などの考案した高周波によ
る抵抗容量測定装置を用いた。これは3゜5 MHzの
高周波電流発生装置と抵抗、容量の検出計を一緒に含ん
だ本体部、それに1cmの長さのコード、その先端に付
帯した円筒状電極ならなっている装置である。電極は同
心円状で直径1mmの中心電極と1.5mmの距離にあ
る内径4mmの外周電極よりなっていて、電極を皮膚に
当てると高周波がそれを介して流れるが、数μAの単位
のものなのでパネルは何の不快感も感じない。この電極
を被検出部に軽く触れると、1秒以内に一定値まで抵抗
が急上昇する。Skin impedance was measured using a high-frequency resistance-capacitance measurement device devised such as pressure intensification. This device consists of a main body that includes a 3.5 MHz high-frequency current generator and a resistance and capacitance detector, a 1 cm long cord, and a cylindrical electrode attached to the tip. The electrodes are concentric and consist of a center electrode with a diameter of 1 mm and an outer electrode with an inner diameter of 4 mm placed at a distance of 1.5 mm. When the electrodes are applied to the skin, high frequency waves flow through them, but they are in the order of a few μA. The panel doesn't feel any discomfort. When this electrode is lightly touched to the detected part, the resistance rises rapidly to a certain value within one second.
この抵抗の逆数はコンダクタンス(Conductan
ce)と呼ばれ、単位はμΦであられしている。このコ
ンダクタンスは皮膚表面の水分量とほぼ比例関係にあり
、更に皮膚は水分含量の多いほど皮膚のしっとり感は良
いと判断されることから、コンダクタンスの増加で皮膚
のしっとり感を数量的に評価することにした。The reciprocal of this resistance is the conductance
ce), and its unit is μΦ. This conductance is almost proportional to the amount of moisture on the skin surface, and the higher the moisture content of the skin, the better the moist feeling of the skin. Therefore, the moist feeling of the skin can be quantitatively evaluated by increasing conductance. It was to be.
第2表は第2実施例にかかるクリームを使用したパネル
の顔面での皮膚インピーダンスにおけるコンダクタンス
を、比較例にかかるクリームの使用パネルの顔面使用部
位と比較したものである。Table 2 compares the conductance in the skin impedance on the face of the panel using the cream according to the second example with the facial application site of the panel using the cream according to the comparative example.
3−N−リボシル尿酸を10−4重量%添加したクリー
ムを使用したパネルの使用部位(右顔面)のコンダクタ
ンスは、上記比較例のクリームを使用したパネルの顔面
での使用部位よりも有意に高い数値として得られること
が理解させる。そして、このことは皮膚に対して、より
しっとり感を与えたクリームは第2実施例にかかるクリ
ームであることを示している。The conductance of the application site (right face) of the panel using the cream containing 10-4% by weight of 3-N-ribosyluric acid is significantly higher than that of the application site on the face of the panel using the cream of the comparative example above. Help students understand that it can be obtained as a numerical value. This shows that the cream that gave a more moist feeling to the skin was the cream according to the second example.
第2表
(以下余白)
同様にして全パネルのコンダクタンスを測定した。3−
N−リボシル尿酸を添加したクリームを使用したパネル
の右顔面のコンダクタンスと、比較例のクリームを使用
した左顔面のコンダクタンスを比較し、
70%以上上昇した場合を著しく効果あり、50%以上
70%未満上昇した場合をやや効果あり、
50%以下の場合を効果なし、
と判定し、その結果を第3表に示す。Table 2 (blank below) The conductance of all panels was measured in the same manner. 3-
The conductance of the right face of the panel using the cream containing N-ribosyluric acid was compared with the conductance of the left face of the panel using the cream of the comparative example, and if it increased by 70% or more, it was considered to be significantly effective, and 50% or more 70%. An increase of less than 50% is considered somewhat effective, and an increase of 50% or less is considered no effect. The results are shown in Table 3.
第3表 一方、皮膚のきめの細やかさはレプリカ法で観察した。Table 3 On the other hand, the fineness of skin texture was observed using the replica method.
シリコンラバーを皮膚に密着させて皮膚の表面像をとり
、次いでこのシリコンラバーにエポキシ樹脂を流し込み
反転像を得た。この反転像の表面に表面粗さ試験機を走
査させて皮膚状態を調べた。そして皮膚表面の起伏の大
きいほど、皮膚のきめが細やかであると判定した。A surface image of the skin was taken by bringing silicone rubber into close contact with the skin, and then an inverted image was obtained by pouring epoxy resin into the silicone rubber. The skin condition was examined by scanning the surface of this inverted image with a surface roughness tester. It was determined that the greater the undulations of the skin surface, the finer the skin texture.
同様にして全パネルの顔面のレプリカ像をとり顔面の左
右を比較し、明らかに右顔面の方が起伏が大きかった場
合を効果ありと判定し、明白な差の認められなかった場
合を効果なしと判定し、その結果を前記第3表にまとめ
ている。In the same way, replica images of the faces of all panels were taken and the left and right sides of the face were compared. If the right side of the face had clearly larger undulations, it was determined that there was an effect, and if there was no obvious difference, it was determined that there was no effect. The results are summarized in Table 3 above.
クリームに添加した3−N−リボシル尿酸は添加濃度に
ほぼ比例して、皮膚のしっとり感、きめの細やかさの改
善に対して優れた効果を発揮することが認められた。It was found that 3-N-ribosyluric acid added to the cream exerts an excellent effect on improving the moist feeling and fineness of the skin almost in proportion to the concentration added.
また、角質層のターンオーバー測定はダンジルクロライ
ド法で観察した。すなわち、ダンジルクロライドを白色
ワセリン中に5重量%配合した軟膏をつくり前記パネル
の前腕部の皮膚に24時間閉塞貼布し、角質層にダンジ
ルクロライドを浸透結合させる。その後同じ部位に1日
2回以上(少なくとも朝夕)クリームを塗布し、毎日ダ
ンジルクロライドの蛍光を測定し、その蛍光が消滅する
までの日数を皮膚角質層のターンオーバーとした。In addition, the turnover of the stratum corneum was measured using the Danzyl chloride method. That is, an ointment containing 5% by weight of danzyl chloride in white petrolatum is prepared and applied to the skin of the forearm of the panel for 24 hours to allow danzyl chloride to penetrate and bind to the stratum corneum. Thereafter, the cream was applied to the same area at least twice a day (at least in the morning and evening), the fluorescence of danzyl chloride was measured every day, and the number of days until the fluorescence disappeared was defined as the turnover of the stratum corneum of the skin.
測定結果は各パネルの日数の平均値で示した。The measurement results are shown as the average value of the number of days for each panel.
なお、通常の皮膚角質層のターンオーバーは、14〜1
6日であるが、老化した皮膚においては18日前後にの
びる。 −
第3表より明らかなように、実施例クリームを使用した
場合には、老化した皮膚に比較し、ターンオーバーが短
くなり、細胞代謝機能を活発化していることが理解され
る。The normal turnover of the stratum corneum of the skin is 14 to 1
It takes about 6 days, but in aging skin it can last around 18 days. - As is clear from Table 3, it can be seen that when the example cream is used, the turnover is shorter than in aged skin, and the cell metabolic function is activated.
以下にその他の実施例を示す。いずれも前記同様の使用
試験の結果、肌あれの防止及び改善に優れた効果を示し
、しかもターンオーバーが短くなることが観察された。Other examples are shown below. As a result of use tests similar to those described above, both showed excellent effects in preventing and improving rough skin, and it was observed that the turnover time was shortened.
裏胤■五
95%エチルアルコール8gにポリビニルピロリドン0
,05g、、tL’イルアルコール0.1g1ポリオキ
シエチレンモノオレエー)1.2g、香料0.2g、パ
ラオキシ安息香酸メチルエステル0.1g、少量の酸化
防止剤、少量の色素を混合溶解した。これを尿酸ソーダ
0.02g、グリセリン5gを精製水85’、33’g
に溶解したものの中に攪拌添加して肌あれの改善効果の
ある化粧水を得た。Uratane■5 8g of 95% ethyl alcohol and 0 polyvinylpyrrolidone
, 05 g, 0.1 g of L'yl alcohol, 1.2 g of polyoxyethylene monooleate), 0.2 g of perfume, 0.1 g of paraoxybenzoic acid methyl ester, a small amount of antioxidant, and a small amount of pigment were mixed and dissolved. Add this to 0.02g of sodium urate, 5g of glycerin, 85'g of purified water, and 33'g.
A lotion with the effect of improving rough skin was obtained by stirring and adding it to the solution.
裏度週1
セチルアルコール1.2g、スクワラン10g1ワセリ
ン2g1パラオキシ安息香酸エチルエステル0.2g、
グリセリンモノステアレート1g1ポリオキシエチレン
(20モル付加)モノステアレート1g1ポリオキシエ
チレン(20モル付加)モノオレエート1g1及び香料
0.1gを70°Cで加熱混合溶解し、同様に3−N−
メチル尿酸0゜1g1ジプロピレングリコ一ル5g1ポ
リエチレングリコール1500 2g、)リエタノール
アミン0.2g、精製水76.2gを75℃で加熱溶解
させた。両者を混合して乳化し、ホモジナイザーにより
乳化粒子を整えて冷却し、W2O型の肌あれ改善効果の
ある乳液を得た。Back week 1 Cetyl alcohol 1.2g, Squalane 10g1 Vaseline 2g1 Paraoxybenzoic acid ethyl ester 0.2g,
1 g of glycerin monostearate, 1 g of polyoxyethylene (20 mole addition) monostearate, 1 g of polyoxyethylene (20 mole addition) monooleate, and 0.1 g of fragrance were heated and mixed and dissolved at 70°C, and 3-N-
0.1 g of methyluric acid, 5 g of dipropylene glycol, 2 g of polyethylene glycol, 0.2 g of reethanolamine, and 76.2 g of purified water were heated and dissolved at 75°C. Both were mixed and emulsified, and the emulsified particles were prepared using a homogenizer and cooled to obtain a W2O type emulsion having an effect of improving rough skin.
夾旙凱ユ
尿酸0.Olg、ジプロピレングリコール5g1トリエ
タノールアミン0.5g、粉末着色料10g1香料0.
Ig、パラオキシ安息香酸エチルエステル0.2g、少
量の酸化防止剤及び精製水60.69gを混合し、均一
に分散させて75℃に加熱した。この中へステアリン酸
1.2g、セチルアルコール0.3g、流動パラフィン
20g1ポリオキシエチレンオレイン酸エステル2gを
混合溶解し75℃に保ったものを徐々に添加し反応乳化
を行ない、冷却しながら攪拌して肌あれ防止効果のある
ファンデーションを得た。0. Olg, dipropylene glycol 5g 1 triethanolamine 0.5g, powder coloring 10g 1 fragrance 0.
Ig, 0.2 g of paraoxybenzoic acid ethyl ester, a small amount of antioxidant, and 60.69 g of purified water were mixed, uniformly dispersed, and heated to 75°C. A mixture of 1.2 g of stearic acid, 0.3 g of cetyl alcohol, 20 g of liquid paraffin, and 2 g of polyoxyethylene oleate was mixed and dissolved into this mixture, and the mixture was kept at 75°C. The mixture was gradually added to react and emulsify, and the mixture was stirred while cooling. I obtained a foundation that has the effect of preventing rough skin.
犬り桝1
95%エチルアルコール8gに1,3−ブチレングリコ
ール5g、ポリオキシエチレン(20モル付加)モノオ
レエート1.5g、7−N−ブチル尿酸0.05g、パ
ラオキシ安息香酸エチルエステル0.2g、香料0.I
g、少量の色素を混合溶解し、ポリビニルアルコール1
0g1ポリエチレングリコール2000 1g、及び精
製水74.15gを80℃で加熱溶解した中に攪拌添加
し、室温まで冷却して肌あれ改善効果のある乾燥被膜型
パックを得た。Inurimasu 1: 8 g of 95% ethyl alcohol, 5 g of 1,3-butylene glycol, 1.5 g of polyoxyethylene (addition of 20 moles) monooleate, 0.05 g of 7-N-butyluric acid, 0.2 g of paraoxybenzoic acid ethyl ester, Fragrance 0. I
g, mix and dissolve a small amount of dye, add polyvinyl alcohol 1
0 g 1 polyethylene glycol 2000 1 g and 74.15 g of purified water were heated and dissolved at 80° C., and the mixture was stirred and added, and the mixture was cooled to room temperature to obtain a dry film-type pack having an effect on improving rough skin.
夾裕孤1
95%エチルアルコール5gにポリオキシエチレンソル
ビタンモノオレート1.2g、アルギン酸ナトリウムO
,Ig、コンドロイチン硫酸ナトリウム0.2g、ヒア
ルロン酸0.1g、ビタミンEアセテ−)0.Ig、グ
リチルリチン酸モノアンモニウム塩0.Ig、パラオキ
シ安息香酸エチルエステルO,Ig、3−N−ラウリル
尿酸0゜05g及び適量の色素を混合し、これをグリセ
リン5g及び精製水88.05gを混合溶解した中へ攪
拌添加して肌あれ改善効果のある美容液を得た。Yuko Kyo 1 5g of 95% ethyl alcohol, 1.2g of polyoxyethylene sorbitan monooleate, O sodium alginate
, Ig, sodium chondroitin sulfate 0.2g, hyaluronic acid 0.1g, vitamin E acetate) 0. Ig, glycyrrhizic acid monoammonium salt 0. Mix Ig, paraoxybenzoic acid ethyl ester O,Ig, 0.05 g of 3-N-lauryl uric acid, and an appropriate amount of pigment, and stir and add this to a mixture of 5 g of glycerin and 88.05 g of purified water. I obtained a beauty serum that has an improving effect.
ベタイン びそれらの塩の・
次に、ベタイン類及びそれらの塩を用いた本発明にかか
る皮膚外用剤の比較試験を行なった。Betaines and Their Salts Next, a comparative test was conducted on the skin external preparations of the present invention using betaines and their salts.
比較試験に供したクリームの組成を第4表に示す。Table 4 shows the composition of the creams used in the comparative test.
なお、クリームの製造法及び試験法については、尿素及
びその誘導体を使用した場合に準する。The cream manufacturing method and testing method shall be the same as when using urea and its derivatives.
(以下余白)
一ハ110 11 12 13
第4表
第5表は、第11実施例のクリームを使用したパネルの
顔面での皮膚インピーダンスにおけるコンダクタンスを
、比較例のクリームの使用パネルの顔面使用部位と比較
したものである。(Margin below) 1ha 110 11 12 13 Table 4 Table 5 shows the conductance in the skin impedance on the face of the panel using the cream of the 11th example, and the facial area of the panel using the cream of the comparative example. This is a comparison.
ホマリンを10−4重量%添加したクリームを使用した
パネルの使用部位(右顔面)のコンダクタンスは上記比
較例のクリームを使用したパネルの顔面での使用部位よ
りも有意に高い数値として得られることが理解される。The conductance of the application site (right face) of the panel using the cream containing 10-4% by weight of Homarin was significantly higher than that of the application site of the panel using the cream of the comparative example above. be understood.
そして、このことは皮膚に対して、よりしっとり感を与
えたクリームは第11実施例にかかるクリームであるこ
とを示している。This shows that the cream that gave a more moist feeling to the skin was the cream according to the eleventh example.
第5表
同様にして全パネルのコンダクタンスを測定した。ホマ
リンを添加したクリームを使用したパネルの右顔面のコ
ンダクタンスと、比較例のクリームを使用した左顔面の
コンダクタンスを比較し、その結果を第6表に示した。The conductance of all panels was measured in the same manner as in Table 5. The conductance of the right face of the panel using the cream containing Homarin was compared with the conductance of the left face of the panel using the cream of the comparative example, and the results are shown in Table 6.
第6表
一方、皮膚のきめの細やかさは前記同様のレプリカ法で
観察した。その結果を第6表にまとめている。Table 6 On the other hand, the fineness of skin texture was observed using the same replica method as described above. The results are summarized in Table 6.
クリームに添加したホマリンは添加濃度にほぼ比例して
、皮膚のしっとり感、きめの細やかさの改善に対して優
れた効果を発揮することが認められた。Homalin added to the cream was found to have an excellent effect on improving skin moisturization and fineness in proportion to the added concentration.
また、角質層のターンオーバー測定はダンジルクロライ
ド法で観察した。In addition, the turnover of the stratum corneum was measured using the Danzyl chloride method.
測定結果は各パネルの日数の平均値で示した。The measurement results are shown as the average value of the number of days for each panel.
第6表より明らかなように、実施例クリームを使用した
場合には、老化した皮膚に比較し、ターンオーバーが短
くなり、細胞代謝機能を活発化していることが理解され
る。As is clear from Table 6, it can be seen that when the Example cream was used, the turnover was shorter than in aged skin, and the cell metabolic function was activated.
以下にその他の実施例を示す。いずれも前記同様の使用
試験の結果、肌あれの防止及び改善に優れた効果を示し
、しかもターンオーバーが短くなることが観察された。Other examples are shown below. As a result of use tests similar to those described above, both showed excellent effects in preventing and improving rough skin, and it was observed that the turnover time was shortened.
実1」LLA
95%エチルアルコール8gにポリビニルピロリドン0
.05g、オレイルアルコール0.Ig。Fruit 1” LLA 95% ethyl alcohol 8g and polyvinylpyrrolidone 0
.. 05g, oleyl alcohol 0. Ig.
ポリオキシエチレンモノオレエート1.2g、香料0.
2g、パラオキシ安息香酸メチルエステル0、Ig、少
量の酸化防止剤、少量の色素を混合溶解した。これをホ
マリンO,001g、グリセリン5gを精製水85.3
49gに溶解したものの中に攪拌添加して肌あれの改善
効果のある化粧水を得た。Polyoxyethylene monooleate 1.2g, fragrance 0.
2g of paraoxybenzoic acid methyl ester, Ig, a small amount of antioxidant, and a small amount of pigment were mixed and dissolved. This is Homarin O, 001g, glycerin 5g and purified water 85.3g.
A lotion having an effect on improving rough skin was obtained by stirring and adding the mixture to 49 g of the solution.
火皿桝11 セチルアルコール1.2g、スクヮラン10 g。Hidara masu 11 1.2 g of cetyl alcohol, 10 g of squalane.
ワセリン2g1パラオキシ安息香酸エチルエステル0.
2g、グリセリンモノステアレート1g1ポリオキシエ
チレン(20モル付加)モノステアレート1g1ポリオ
キシエチレン(20モル付加)モノオレエートIg、及
び香料0.Igを70’Cで加熱混合溶解し、同様にト
リゴネリン0.Ig。Vaseline 2g 1 paraoxybenzoic acid ethyl ester 0.
2 g, glycerin monostearate 1 g 1 polyoxyethylene (20 mole addition) monostearate 1 g polyoxyethylene (20 mole addition) monooleate Ig, and fragrance 0. Ig was heated and mixed and dissolved at 70'C, and trigonelline was added in the same manner. Ig.
ジプロピレングリコール5g1ポリエチレングリコール
1500 2g、 トリエタノールアミン0゜2g、
精製水76.2gを75℃で加熱溶解させた。両者を混
合して乳化し、ホモジナイザーにより乳化粒子を整えて
冷却し、W2O型の肌あれ改善効果のある乳液を得た。Dipropylene glycol 5g 1 polyethylene glycol 1500 2g, triethanolamine 0゜2g,
76.2 g of purified water was heated and dissolved at 75°C. Both were mixed and emulsified, and the emulsified particles were prepared using a homogenizer and cooled to obtain a W2O type emulsion having an effect on improving rough skin.
裏血皿11
リジンベタイン0.05g、ジプロピレングリコール5
g1 トリエタノールアミン0.5g、粉末着色料Lo
g、香料0.1g、パラオキシ安息香酸エチルエステル
0.2g、少量の酸化防止剤及び精製水60.65gを
混合し、均一に分散させて75℃に加熱した。この中へ
ステアリン酸1゜2g1セチルアルコール0.3g、流
動パラフィン20g、ポリオキシエチレンオレイン酸エ
ステル2gを混合溶解し75℃に保ったものを徐々に添
加し反応乳化を行ない、冷却しながら攪拌して肌あれ防
止効果のあるファンデーションを得た。Lined blood plate 11 Lysine betaine 0.05g, dipropylene glycol 5
g1 Triethanolamine 0.5g, powder colorant Lo
g, 0.1 g of perfume, 0.2 g of paraoxybenzoic acid ethyl ester, a small amount of antioxidant, and 60.65 g of purified water were mixed, uniformly dispersed, and heated to 75°C. A mixture of 1.2 g of stearic acid, 0.3 g of cetyl alcohol, 20 g of liquid paraffin, and 2 g of polyoxyethylene oleate was mixed and dissolved into this mixture and kept at 75°C, and the mixture was gradually added to react and emulsify, followed by stirring while cooling. I obtained a foundation that has the effect of preventing rough skin.
裏五皿1ユ
95%エチルアルコール8gに1.3−ブチレングリコ
ール5g1ポリオキシエチレン(20モル付加)モノオ
レエート1,5g、タウロベタイン0.2g、パラオキ
シ安息香酸エチルエステル0.2g、香料0.1g、少
量の色素を混合溶解し、ポリビニルアルコール10g1
ポリエチレングリコール2000 1g、及び精製水7
4.18gを80℃で加熱溶解した中に攪拌添加し、室
温まで冷却して肌あれ改善効果のある乾燥被膜型パック
を得た。1 unit 95% ethyl alcohol 8g 1.3-butylene glycol 5g 1 polyoxyethylene (addition of 20 moles) 1.5g monooleate, taurobetaine 0.2g, paraoxybenzoic acid ethyl ester 0.2g, fragrance 0.1g , mix and dissolve a small amount of pigment, and add 10 g of polyvinyl alcohol.
1g of polyethylene glycol 2000 and 7 parts of purified water
4.18 g of the solution was stirred and added to a solution heated and dissolved at 80° C., and the mixture was cooled to room temperature to obtain a dry film-type pack having an effect on improving rough skin.
丸癒五11
95%エチルアルコール5gにポリオキシエチレンソル
ビタンモノオレート1.2g、アルギン酸ナトリウム0
.1g、コンドロイチン硫酸ナトリウム0.2g、ヒア
ルロン酸0.1g、ビタミンEアセテート0.1g1グ
リチルリチン酸モノアンモニウム塩0.1g、パラオキ
シ安息香酸エチルエステル0.1g、ホマリン0.05
g及び適量の色素を混合し、これをグリセリン5g及び
精製水88.05gを混合溶解した中へ攪拌添加して肌
あれ改善効果のある美容液を得た。Maruyugo 11 95% ethyl alcohol 5g, polyoxyethylene sorbitan monooleate 1.2g, sodium alginate 0
.. 1g, sodium chondroitin sulfate 0.2g, hyaluronic acid 0.1g, vitamin E acetate 0.1g1 glycyrrhizic acid monoammonium salt 0.1g, paraoxybenzoic acid ethyl ester 0.1g, homarin 0.05
g and an appropriate amount of pigment were mixed, and the mixture was stirred and added to a mixed solution of 5 g of glycerin and 88.05 g of purified water to obtain a beauty serum having an effect on improving rough skin.
[発明の効果]
本発明は以上説明したように構成されているので、以下
に記載されるような効果を奏する。[Effects of the Invention] Since the present invention is configured as described above, it produces the effects described below.
請求項1記載の皮膚外用剤によれば、尿酸及びその誘導
体を含むこととしたので、あらゆる種類の肌あれの防止
及び改善に極めて有効である。According to the skin external preparation according to claim 1, since it contains uric acid and its derivatives, it is extremely effective in preventing and improving all kinds of skin roughness.
請求項2記載の皮膚外用剤によれば、ベタイン類及びそ
れらの塩を含むこととしたので、あらゆる種類の肌あれ
の防止及び改善に対して極めて有用である。According to the skin external preparation according to claim 2, since it contains betaines and their salts, it is extremely useful for preventing and improving all kinds of skin roughness.
Claims (2)
または二種以上の化合物を含むことを特徴とする皮膚外
用剤。(1) An external skin preparation characterized by containing one or more compounds selected from the group consisting of uric acid and its derivatives.
た一種または二種以上の化合物を含むことを特徴とする
皮膚外用剤。(2) A skin external preparation characterized by containing one or more compounds selected from the group consisting of betaines and their salts.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63103481A JP2775154B2 (en) | 1988-04-26 | 1988-04-26 | Anti-skin and anti-aging agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63103481A JP2775154B2 (en) | 1988-04-26 | 1988-04-26 | Anti-skin and anti-aging agents |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01275511A true JPH01275511A (en) | 1989-11-06 |
JP2775154B2 JP2775154B2 (en) | 1998-07-16 |
Family
ID=14355201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63103481A Expired - Lifetime JP2775154B2 (en) | 1988-04-26 | 1988-04-26 | Anti-skin and anti-aging agents |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2775154B2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10175848A (en) * | 1996-10-18 | 1998-06-30 | Shiseido Co Ltd | Powdery skin detergent |
US5833969A (en) * | 1997-06-25 | 1998-11-10 | Yamahatsu Sangyo Kaisha, Ltd. | Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition |
EP0875241A3 (en) * | 1997-04-28 | 1999-03-24 | Yamahatsu Sangyo Kaisha, Ltd. | Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition |
WO2002053127A1 (en) * | 2000-12-28 | 2002-07-11 | Shiseido Company, Ltd. | Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
WO2002083087A1 (en) * | 2001-04-13 | 2002-10-24 | Otsuka Pharmaceutical Co., Ltd. | Sugar intake promoters |
GB2428576A (en) * | 2005-08-01 | 2007-02-07 | James Bruce Clapp | Anti-aging skin cream |
JP2011512397A (en) * | 2008-02-22 | 2011-04-21 | セダーマ | Moisturizing cosmetic composition comprising a combination of homarin and erythritol |
US8791045B2 (en) | 2011-11-09 | 2014-07-29 | Kimberly-Clark Worldwide, Inc. | Non-tacky wetness indicator composition for application on a polymeric substrate |
US9119780B2 (en) | 2013-10-30 | 2015-09-01 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of proactive chemistry |
US9585826B2 (en) | 2012-11-07 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of active chemistry |
US9889222B2 (en) | 2011-11-09 | 2018-02-13 | Kimberly-Clark Worldwide, Inc. | Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666863A (en) * | 1968-03-06 | 1972-05-30 | Medisan Ab | Skin-treating composition and vehicle for skin-treating agents |
JPS5089406A (en) * | 1973-12-11 | 1975-07-17 | ||
JPS5148441A (en) * | 1974-10-22 | 1976-04-26 | Kowa Co | HIFUSHORISOSEIBUTSUNO ANTEIKAHOHO |
JPS51148042A (en) * | 1975-06-14 | 1976-12-18 | Kanebo Ltd | Skin toiletry |
JPS5464641A (en) * | 1977-10-28 | 1979-05-24 | Baanaado Maikuruzu Edouin | Antiibacterial composition |
JPS5610156A (en) * | 1979-06-30 | 1981-02-02 | Goldschmidt Ag Th | Manufacture of betaine |
JPS58206510A (en) * | 1982-05-27 | 1983-12-01 | Kobayashi Kooc:Kk | Agent for removing eye makeup |
JPS60152415A (en) * | 1984-01-18 | 1985-08-10 | Sato Seiyaku Kk | Remedy for pimple and pharmaceutical preparation for remedying pimple consisting of carrier impregnated therewith |
JPS61183204A (en) * | 1985-02-07 | 1986-08-15 | Riken Vitamin Co Ltd | Cosmetic |
JPS6272796A (en) * | 1985-09-27 | 1987-04-03 | 株式会社資生堂 | Detergent composition for human body |
JPS62138594A (en) * | 1985-12-12 | 1987-06-22 | 花王株式会社 | cleaning composition |
JPS62205198A (en) * | 1986-03-05 | 1987-09-09 | 日本油脂株式会社 | Liquid detergent composition for body |
JPS62298566A (en) * | 1986-06-04 | 1987-12-25 | シグマ―タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | D(+)-carnitine alkylamide |
JPS6452712A (en) * | 1987-08-24 | 1989-02-28 | Nissan Setsuken Kk | Liquid detergent composition |
-
1988
- 1988-04-26 JP JP63103481A patent/JP2775154B2/en not_active Expired - Lifetime
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666863A (en) * | 1968-03-06 | 1972-05-30 | Medisan Ab | Skin-treating composition and vehicle for skin-treating agents |
JPS5089406A (en) * | 1973-12-11 | 1975-07-17 | ||
JPS5148441A (en) * | 1974-10-22 | 1976-04-26 | Kowa Co | HIFUSHORISOSEIBUTSUNO ANTEIKAHOHO |
JPS51148042A (en) * | 1975-06-14 | 1976-12-18 | Kanebo Ltd | Skin toiletry |
JPS5464641A (en) * | 1977-10-28 | 1979-05-24 | Baanaado Maikuruzu Edouin | Antiibacterial composition |
JPS5610156A (en) * | 1979-06-30 | 1981-02-02 | Goldschmidt Ag Th | Manufacture of betaine |
JPS58206510A (en) * | 1982-05-27 | 1983-12-01 | Kobayashi Kooc:Kk | Agent for removing eye makeup |
JPS60152415A (en) * | 1984-01-18 | 1985-08-10 | Sato Seiyaku Kk | Remedy for pimple and pharmaceutical preparation for remedying pimple consisting of carrier impregnated therewith |
JPS61183204A (en) * | 1985-02-07 | 1986-08-15 | Riken Vitamin Co Ltd | Cosmetic |
JPS6272796A (en) * | 1985-09-27 | 1987-04-03 | 株式会社資生堂 | Detergent composition for human body |
JPS62138594A (en) * | 1985-12-12 | 1987-06-22 | 花王株式会社 | cleaning composition |
JPS62205198A (en) * | 1986-03-05 | 1987-09-09 | 日本油脂株式会社 | Liquid detergent composition for body |
JPS62298566A (en) * | 1986-06-04 | 1987-12-25 | シグマ―タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | D(+)-carnitine alkylamide |
JPS6452712A (en) * | 1987-08-24 | 1989-02-28 | Nissan Setsuken Kk | Liquid detergent composition |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10175848A (en) * | 1996-10-18 | 1998-06-30 | Shiseido Co Ltd | Powdery skin detergent |
EP0875241A3 (en) * | 1997-04-28 | 1999-03-24 | Yamahatsu Sangyo Kaisha, Ltd. | Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition |
US6027719A (en) * | 1997-04-28 | 2000-02-22 | Yamahatsu Sangyo Kaisha, Ltd. | Aqueous cosmetic composition containing stably solubilized uric acid and water-soluble polymer and method for stably solubilizing uric acid in aqueous cosmetic composition |
US5833969A (en) * | 1997-06-25 | 1998-11-10 | Yamahatsu Sangyo Kaisha, Ltd. | Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition |
EP0987009A1 (en) * | 1997-06-25 | 2000-03-22 | Yamahatsu Sangyo Kaisha, Ltd. | Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition |
WO2002053127A1 (en) * | 2000-12-28 | 2002-07-11 | Shiseido Company, Ltd. | Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
CN1294896C (en) * | 2000-12-28 | 2007-01-17 | 株式会社资生堂 | Agents for inhibiting or restoring skin damage caused by drying and method of evaluating the same |
US7820636B2 (en) | 2001-04-13 | 2010-10-26 | Otsuka Pharmaceutical Co., Ltd. | Sugar intake promoters |
WO2002083087A1 (en) * | 2001-04-13 | 2002-10-24 | Otsuka Pharmaceutical Co., Ltd. | Sugar intake promoters |
CN1305460C (en) * | 2001-04-13 | 2007-03-21 | 大塚制药株式会社 | Sugar intake promoters |
GB2428576A (en) * | 2005-08-01 | 2007-02-07 | James Bruce Clapp | Anti-aging skin cream |
JP2011512397A (en) * | 2008-02-22 | 2011-04-21 | セダーマ | Moisturizing cosmetic composition comprising a combination of homarin and erythritol |
US8791045B2 (en) | 2011-11-09 | 2014-07-29 | Kimberly-Clark Worldwide, Inc. | Non-tacky wetness indicator composition for application on a polymeric substrate |
US9889222B2 (en) | 2011-11-09 | 2018-02-13 | Kimberly-Clark Worldwide, Inc. | Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness |
US9585826B2 (en) | 2012-11-07 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of active chemistry |
US9119780B2 (en) | 2013-10-30 | 2015-09-01 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of proactive chemistry |
Also Published As
Publication number | Publication date |
---|---|
JP2775154B2 (en) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5965145A (en) | Use of honey as keratolytic agent for improving the radiance and the complexion of the skin and treating wrinkles | |
JP3483988B2 (en) | Skin preparation | |
JPS59134706A (en) | Cosmetic | |
JPH09291011A (en) | Composition suitable for eternal use | |
JPH07277939A (en) | Skin external preparation | |
JPH01275511A (en) | External drug for skin | |
JP2005082600A (en) | How to treat skin symptoms | |
JPH09255547A (en) | External preparation for skin | |
JP3251635B2 (en) | External preparation for skin | |
JPS624362B2 (en) | ||
JPH09183718A (en) | Composition suitable for external application | |
JPH10114670A (en) | Composition suitable for external use | |
JP2011042613A (en) | Anti-aging skin care preparation and anti-aging cosmetic | |
JPH069422A (en) | Promoter for biosynthesis of hyaluronic acid | |
JPH0995432A (en) | Preparation for external use for skin | |
JPH0551314A (en) | Skin cosmetics | |
JP3507635B2 (en) | Composition suitable for external use | |
JPS62169711A (en) | Skin cosmetic | |
JP2001278783A (en) | Collagen production promoter | |
JP3505003B2 (en) | External preparation | |
JPH05301812A (en) | Skin external preparation | |
JPS61205204A (en) | External preparation for skin | |
JP3441387B2 (en) | Moisturizer, skin cosmetics and bath additives | |
JPH09255546A (en) | External preparation for skin | |
JP2003335651A (en) | Skin care preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |